AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00986284
Drug: gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with EGFR mutation in exon 19 or 21 will be administrated with gefitinib as neoadjuvant therapy. Then evaluated for response and then operation for operable patients.
Trial: NCT02803138
Drug: Ombitasvir/paritaprevir/ritonavir
RxNorm normalized name: ombitasvir/paritaprevir/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Co-formulated tablet
Trial: NCT02803138
Drug: Dasabuvir
RxNorm normalized name: Dasabuvir
DrugBank: Dasabuvir (DB09183)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet
Trial: NCT02803138
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet
Trial: NCT04464200
Drug: 19(T2)28z1xx CAR T cells
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-7 days following the completion of the conditioning chemotherapy, patients will receive the CAR- T cells by IV infusion over 1-3 days depending on the dose level and formulation of the final CAR- T cells.
Trial: NCT01513200
Drug: Unfractionated heparin (UFH)
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: UFH solution for infusion Initially 60U/kg bolus followed by intravenous infusion (12U/kg/hr) for approximately 11 hours
Trial: NCT01513200
Drug: Saline (0.9%, sterile, for infusion)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline (placebo) Constant IV infusion for 4 hours
Trial: NCT00191087
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00204243
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: surgically implanted naltrexone releasing during 5 to 6 months
Trial: NCT00204243
Drug: Methadone
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methadone maintenance treatment, flexible high dose (80 to 120 mg / Day)
Trial: NCT01606878
Drug: Crizotinib
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT01606878
Drug: Dexrazoxane Hydrochloride
RxNorm normalized name: Dexrazoxane Hydrochloride
DrugBank: Dexrazoxane (DB00380)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01606878
Drug: Topotecan Hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01606878
Drug: Vincristine Sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00084461
Drug: romidepsin
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02719015
Drug: rAd.CD40L
RxNorm normalized name: rAd.CD40L
DrugBank: Ad-ISF35 (DB17181)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Escalation Phase Starting Dose: 5x10\^10 vp per tumor as an injection directly into 1-3 tumors every 3 weeks. Same tumors injected for each of the 4 injections at week 0, 3, 6 and 9. If the dose well tolerated, the rAd.CD40L escalated to 1x10\^11 vp. Subsequently enrolled patients injected at the same dose of 1x10\^11 vp. Number of injected sites/tumors increased to two sites/lesions if patients have \>/=2 injectable lesions, at the same injection dose of 1x10\^10 up to three separate sites/lesions if patients have \> 3 injectable lesions.~Dose Expansion Phase Starting Dose: MTD from Dose Escalation Phase.
Trial: NCT02719015
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose Escalation and Expansion Phases: 2 mg/kg by vein every 3 weeks.
Trial: NCT00398632
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dosage form: capsule. dosage: 60 mg. frequency: once daily, or twice daily if 120 mg/day is needed to control symptoms of major depression. duration: 12 weeks
Trial: NCT00586664
Drug: Bepotastine Besilate Ophthalmic Solution 1.0%
DrugBank: Bepotastine (DB04890)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sterile ophthalmic solution
Trial: NCT04173793
Drug: AK102
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT04173793
Drug: Statins and/or Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lipid-lowering therapies
Trial: NCT01439815
Drug: Fluticasone Propionate Nasal Spray
RxNorm normalized name: fluticasone propionate Metered Dose Nasal Spray
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: two sprays in each nostril once daily
Trial: NCT00003673
Drug: gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01581073
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa is used for targeting Hb level of 11-13g/dL in high Hb group, and 9-11g/dL in low Hb group.
Trial: NCT01274273
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 MIU/m2 s.c. two times daily, 5 days per week, weeks 1 and 2, every 28-day-cycle, for a maximum of 9 cycles (i.e.for a maximum of 9 months).
Trial: NCT01274273
Drug: Interferon Alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IFN-alfa given as one priming-week of daily IFN 3.0 MIU, followed by up to 9 treatment cycles (i.e. for a maximum of 9 months) with IFN-alfa 3.0 MIU as a fixed dose s.c. once daily - 5 days per week.
Trial: NCT01274273
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab doses of 10 mg per kilogram of body weight, given every two weeks i.v. until disease progression, unacceptable toxicity, withdrawal of consent or a maximum of 1 year following obtaining no evidence of disease (NED).
Trial: NCT01204073
Drug: TAK-441
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-441 will be administered as an oral tablet as follows:~Patients enrolled in the dose escalation cohorts will receive:~* A single-dose administration on Day 1, followed by a 1-week washout period during which pharmacokinetics is assessed~* Continuous daily dosing on Days 8 through 28 in Cycle 1~* In subsequent cycles, continuous daily dosing over 21 days, repeated continuously~Patients enrolled in the expansion cohorts will receive continuous daily dosing on Days 1 through 21 of each 21-day cycle
Trial: NCT04315831
Drug: Transdermal Buprenorphine
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intervention will be applied for patients with moderate to severe cancer pain
Trial: NCT02996448
Drug: NDV-3A
RxNorm normalized name: GD-HP-DO 3A
DrugBank: Gadoteridol (DB00597)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A vaccine containing recombinant Candida albicans agglutinin-like sequence 3 (rAls3) protein as the antigen, formulated with AlOH adjuvant in phosphate buffered saline. Participants will receive a single 0.5 mL dose containing 300 micrograms of rAls3 and 0.5 mg of aluminum as AlOH, delivered via intramuscular injection.
Trial: NCT01093040
Drug: CAT-354
RxNorm normalized name: Spotted cat
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg CAT-354 or placebo given SC on Day 1
Trial: NCT01093040
Drug: CAT-354
RxNorm normalized name: Spotted cat
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg CAT-354 or placebo given SC on Day 1
Trial: NCT01093040
Drug: CAT 354
RxNorm normalized name: Spotted cat
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg CAT-354 or placebo given SC on Day 1
Trial: NCT00368914
Drug: sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00732784
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dosage form: tablets Dosage: 400 mg Frequency \& duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
Trial: NCT01018342
Drug: Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg
DrugBank: Nitrofurantoin (DB00698)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01035593
Drug: recombinant C1 inhibitor
RxNorm normalized name: C1 Inhibitor (Recombinant)
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100units/kg IV for seven consecutive days (once daily on PP/IVIG days, twice daily on non-PP/IVIG days).
Trial: NCT00315328
Drug: Atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine 1% each weekend day in the sound eye
Trial: NCT00984828
Drug: velcade
RxNorm normalized name: Velcade
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: velcade 1.3mg/m2 D1, 4, 8 and 11
Trial: NCT00753909
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin (IV) 3 AUC on day 1 and day 15 every 4 weeks for 6 cycles
Trial: NCT00753909
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (IV) 10 mg/kg on day 1 and day 15 every 4 weeks for 6 cycles Followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression
Trial: NCT00753909
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (IV) 140 mg/m2,on day 1 and day 15 every 4 weeks for 6 cycles
Trial: NCT01447212
Drug: Hydromorphone, Injectable
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase I: 3x daily, up to 500mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable hydromorphone; 2) switch to oral hydromorphone, for another 6 months.
Trial: NCT01447212
Drug: Diacetylmorphine, injectable
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase I: 3x daily, up to 1,000mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable diacetylmorphine; 2) switch to oral diacetylmorphine, for another 6 months.
Trial: NCT01447212
Drug: Hydromorphone, liquid oral
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study Phase II: After 6 months of receiving Hydromorphone injectable , participants will be randomized to stay on injectable hydromorphone or switch to oral hydromorphone, for another six months. Oral = experimental; injectable = active comparator
Trial: NCT01019278
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00791154
Drug: AMG 479
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 479 is administered to subjects
Trial: NCT01447212
Drug: Diacetylmorphine, liquid oral
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study Phase II: After 6 months of receiving Diacetylmorphine injectable, participants will be randomized to stay on injectable Diacetylmorphine or switch to oral Diacetylmorphine, for another six months. Oral = experimental; injectable = active comparator
Trial: NCT01086527
Drug: 10 mg tablet of montelukast (Singulair)
RxNorm normalized name: montelukast 10 MG
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fasting patients will take a single 10 mg tablet of montelukast with 240 ml of Gatorade. Eight blood samples will be drawn to assess the plasma concentration of montelukast over the subsequent 12 hours.
Trial: NCT00791154
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide is administered to subjects
Trial: NCT02232880
Drug: Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day \[Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day\], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.
Trial: NCT01585584
Drug: Boceprevir
RxNorm normalized name: Boceprevir
DrugBank: Boceprevir (DB08873)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will receive a 4-week lead-in with Peginterferon and Ribavirin therapy, followed by 24 weeks of Pegetron 1.5microg/kg + weight-based ribavirin + boceprevir 800mg tid. HCV RNA (Cobas TaqMan) will be measured at baseline and at treatment weeks 4, 6,8,12,16,20,24 and 28, and post-treatment weeks 12 and 24 (to obtain SVR-12 and SVR-24 results).
Trial: NCT00527488
Drug: Degarelix
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two doses of 16 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
Trial: NCT00527488
Drug: Degarelix
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of 32 mg administered as a single administration will be evaluated for 42 days.
Trial: NCT00791154
Drug: AMG 102
RxNorm normalized name: AMG 102
DrugBank: Rilotumumab (DB11972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 102 is administered to subjects
Trial: NCT00791154
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin is administered to some subjects in combination
Trial: NCT00791154
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin is administered to some subjects in combination
Trial: NCT00527488
Drug: Degarelix
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two doses of 32 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
Trial: NCT00527488
Drug: Degarelix
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of 64 mg administered as a single administration will be evaluated for 42 days.
Trial: NCT02848443
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Concentrate for solution for infusion containing 5mg/ml of oxaliplatin, administered intravenously at the dose of 65 to 85 mg/m2, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
Trial: NCT02848443
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Concentrate for solution for infusion containing 25mg/ml of bevacizumab, administered intravenously at the dose of 5 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
Trial: NCT02848443
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Concentrate for solution for infusion containing 10mg/ml of nivolumab, administered intravenously at the dose of 3 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
Trial: NCT00997672
Drug: Lithium Carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
Trial: NCT03874260
Drug: Fenofibrate
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate vs statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate placebo / once a day, P.O
Trial: NCT01728363
Drug: Antibiotic
RxNorm normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticarcillin-clavulanate/Timentin is an antibiotic used to treat a wide variety of bacterial infections. Rifampin/Rifadin/Rimatane is an antibiotic and first line antituberculotic. Clindamycin/Cleocin is an antibiotic used to treat a wide variety of bacterial infections and serious bacterial infections.
Trial: NCT00004393
Drug: risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03739996
Drug: Long-Acting Injectable Cabotegravir (CAB LA)
DrugBank: Cabotegravir (DB11751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 mg loading dose followed by 400 mg maintenance doses administered by intramuscular (IM) injection
Trial: NCT00534261
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IM injection
Trial: NCT01967381
Drug: Methamphetamine (Desoxyn®)
RxNorm normalized name: methamphetamine Oral Tablet [Desoxyn]
DrugBank: Metamfetamine (DB01577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The pharmacodynamic effects of methamphetamine (Desoxyn®) will be determined during placebo, oxazepam (Serax®), naltrexone (Revia®) and combined oxazepam and naltrexone maintenance.
Trial: NCT03716804
Drug: Tablet Nitrofurantoin
RxNorm normalized name: nitrofurantoin Oral Tablet
DrugBank: Nitrofurantoin (DB00698)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet Nitrofurantoin (100 mg), two times daily in 12 hours interval for 7 days
Trial: NCT03460015
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During the first 30 minutes after randomization, patients will be treated with propofol (same dosage as the propofol group).~Once the AnaConDa® system is installed, sevoflurane administration will begin (propofol is stopped).
Trial: NCT03460015
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the control group, sedation will be maintained with the above objective (RASS between -4 and -5, BIS between 40 and 60) until the patient is extubated.~In the sevoflurane group, propofol is administrated during the first 30 minutes after the randomization and when the AnaConDa® system is installed propofol is stopped.
Trial: NCT03757013
Drug: Apremilast
RxNorm normalized name: Apremilast
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Apremilast
Trial: NCT00139867
Drug: PARCOPA
RxNorm normalized name: Parcopa
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02955251
Drug: ABBV-428
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-428 will be administered by intravenous infusion in 28-day dosing cycles on Day 1 and Day 15.
Trial: NCT02955251
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab will be administered by intravenous infusion according to approved dose and dosing schedules.
Trial: NCT00729222
Drug: rolofylline
RxNorm normalized name: Rolofylline
DrugBank: Rolofylline (DB12670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rolofylline 30 mg IV infusion over 4 hours.
Trial: NCT02850081
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A lipid-lowering agent and for prevention of events associated with cardiovascular disease.~10 mg or 80 mg capsules
Trial: NCT00627146
Drug: ChAgly CD3
RxNorm normalized name: Muromonab-Cd3
DrugBank: Muromonab (DB00075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 days treatment 8mg/d intravenous
Trial: NCT01145638
Drug: iron isomaltoside 1000
RxNorm normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenously as bolus or infusion, 500 mg or 1000mg up to full replacement dose
Trial: NCT00789074
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Varenicline 1mg twice daily
Trial: NCT01974765
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All enrolled patients will be treated with enzalutamide 160mg by mouth QD. Study drugs will be self-administered by patients. A cycle is 28 days.
Trial: NCT01528865
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Creatinine Clearance (mL/min): ≥50, Recommended Dosage of Epivir: 150 mg twice daily or 300 mg once daily.~Creatinine Clearance (mL/min): 30-49, Recommended Dosage of Epivir: 150 mg once daily.~Subjects will be taking drug for 16 weeks.
Trial: NCT01528865
Drug: Tenofovir disoproxil fumarate
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg once a day p.o. for 16 weeks.